The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 29, 2025

Filed:

Aug. 13, 2019
Applicant:

Akeso Biopharma, Inc., Guangdong, CN;

Inventors:

Baiyong Li, Guangdong, CN;

Yu Xia, Guangdong, CN;

Peng Zhang, Guangdong, CN;

Zhongmin Maxwell Wang, Guangdong, CN;

Assignee:

Akeso Biopharma, Inc., Guangdong, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2005.12); A61K 47/68 (2016.12); A61P 19/02 (2005.12); A61P 37/06 (2005.12); C07K 16/24 (2005.12); A61K 39/00 (2005.12);
U.S. Cl.
CPC ...
C07K 16/245 (2012.12); A61K 47/6845 (2017.07); A61P 19/02 (2017.12); A61P 37/06 (2017.12); C07K 16/244 (2012.12); A61K 2039/505 (2012.12); C07K 2317/21 (2012.12); C07K 2317/24 (2012.12); C07K 2317/31 (2012.12); C07K 2317/52 (2012.12); C07K 2317/565 (2012.12); C07K 2317/622 (2012.12); C07K 2317/76 (2012.12); C07K 2317/92 (2012.12);
Abstract

The present invention belongs to the field of immunology, and relates to an anti-IL-1β antibody and pharmaceutical composition thereof and use of the same. Specifically, the present invention relates to an anti-IL-1β antibody or an antigen-binding fragment thereof, wherein a heavy chain variable region of the antibody comprises HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NO: 17-SEQ ID NO: 19, respectively; and a light chain variable region of the antibody comprises LCDR1-LCDR3 set forth in SEQ ID NO: 20-SEQ ID NO: 22, respectively. The antibody disclosed herein can effectively bind to human IL-1B, block the binding of IL-1B to a receptor IL-1R1 thereof, and inhibit the activation of downstream signaling pathways of IL-1B; having the potential of being used for preparing a medicament for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes in children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors.


Find Patent Forward Citations

Loading…